IFNG and cancer: A phase II trial has recently evaluated IFNγ-DC-derived exosomes loaded with MHC I/II confined cancer antigens as maintenance immunotherapy after chemotherapy in advanced patients without tumor progression, and exosomes may be used as anticancer vaccines in the future.